At any cost: how Ukrainians think about self‐defense against Russia

How do populations facing external aggression view the costs and benefits of self-defense? In Western countries, war support has been shown to follow cost–benefit calculations, resembling the moral principle of proportionality. A categorical position, in contrast, means supporting self-defense regardless of the costs. To evaluate which moral principle populations facing external aggression follow, we conducted a conjoint experiment with 1,160 Ukrainians in July 2022. We examine support for different strategies Ukraine could pursue against Russia, which vary regarding the political autonomy and territorial integrity they afford and three costs: civilian and military fatalities, and nuclear risk. We find that Ukrainians do not trade off autonomy or territory against these costs. A new method to rank conjoint-attributes, computing “nested” marginal means, shows that respondents categorically reject political or territorial concessions, regardless of costs. This provides first experimental evidence that populations resisting external aggression do not subject war outcomes to cost–benefit calculations

Utilizing UV and Visible Sensors on Micro Satellites to Demonstrate Target Acquisition and Tracking

The Distributed Sensing Experiment (DSE) program is a technology demonstration of target acquisition, tracking, and three-dimensional track development using a constellation of three micro satellites. DSE will demonstrate how micro satellites, working singly and as a group, can observe test-missile boost and ballistic-flight events. The overarching program objective is to demonstrate a means of fusing measurements from multiple sensors into a composite track. To perform this demonstration, each DSE micro satellite will acquire and track a target, determine a two-dimensional direction and movement rate for each, communicate observations to other DSE satellites, determine a three-dimensional target position and velocity, and relay this information to ground systems. A key design parameter of the program is incorporating commercial off-the-shelf (COTS) hardware and software to reduce risk and control costs, while maintaining performance. Having completed a successful Critical Design Review, the program is currently in fabrication, integration, and test phase. The constellation of satellites is scheduled for launch in CY2009. This paper describes the status and capabilities of the UV and visible sensor payloads, as well as the algorithms and software being developed to achieve the DSE mission

BACH1 Ser919Pro variant and breast cancer risk

BACKGROUND: BACH1 (BRCA1-associated C-terminal helicase 1; also known as BRCA1-interacting protein 1, BRIP1) is a helicase protein that interacts in vivo with BRCA1, the protein product of one of the major genes for hereditary predisposition to breast cancer. Previously, two BACH1 germ line missense mutations have been identified in early-onset breast cancer patients with and without family history of breast and ovarian cancer. In this study, we aimed to evaluate whether there are BACH1 genetic variants that contribute to breast cancer risk in Finland. METHODS: The BACH1 gene was screened for germ line alterations among probands from 43 Finnish BRCA1/2 negative breast cancer families. Recently, one of the observed common variants, Ser-allele of the Ser919Pro polymorphism, was suggested to associate with an increased breast cancer risk, and was here evaluated in an independent, large series of 888 unselected breast cancer patients and in 736 healthy controls. RESULTS: Six BACH1 germ line alterations were observed in the mutation analysis, but none of these were found to associate with the cancer phenotype. The Val193Ile variant that was seen in only one family was further screened in an independent series of 346 familial breast cancer cases and 183 healthy controls, but no additional carriers were observed. Individuals with the BACH1 Ser919-allele were not found to have an increased breast cancer risk when the Pro/Ser heterozygotes (OR 0.90; 95% CI 0.70–1.16; p = 0.427) or Ser/Ser homozygotes (OR 1.02; 95% CI 0.76–1.35; p = 0.91) were compared to Pro/Pro homozygotes, and there was no association of the variant with any breast tumor characteristics, age at cancer diagnosis, family history of cancer, or survival. CONCLUSION: Our results suggest that the BACH1 Ser919 is not a breast cancer predisposition allele in the Finnish study population. Together with previous studies, our results also indicate that although some rare germ line variants in BACH1 may contribute to breast cancer development, the contribution of BACH1 germline alterations to familial breast cancer seems marginal

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

A Constellation of Three Micro Satellites uses UV and Visible Sensors to Demonstrate Target Acquisition and Tracking

The Distributed Sensing Experiment (DSE) program demonstrates the technology of using micro satellites to perform target acquisition, tracking, and three-dimensional track development using a visible camera payload. DSE is a concept demonstration to show how micro satellites, working singly and as a group, can perform a large part of the missile defense function at a much lower cost than traditional systems. A key design parameter of the program is incorporating commercial-off-the-shelf (COTS) hardware and software to reduce risk and cost, while maintaining performance. Having completed a successful Critical Design Review, the program is currently in fabrication, integration, and test phase. The constellation of satellites is scheduled for launch in CY2009. This paper describes the status and capabilities of the UV and visible sensor payloads, as well as algorithms and software being developed to achieve the DSE mission